

LISTING OF CLAIMS:

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

Claims 1-21 (canceled)

22. (Currently amended): A pharmaceutical composition to treat hepatic fibrosis comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors,

wherein said unitary dose is from about 10^7 to about 10^{14} viral particles;

wherein the adenoviral vectors comprise an adenoviral genome of serotype Ad5 replaced with deletions at E1 and inserted with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter, a tissue-specific promoter, or a combination thereof, and wherein the DNA sequence that encodes for one or more a therapeutic protein proteins for the treatment of hepatic fibrotic disorders in organs;

and a pharmaceutically compatible carrier;

wherein the composition is suitable for intravenous administration; and,

wherein the therapeutic protein proteins for the treatment of fibrotic disorders are is selected from the group consisting of a latent or active protein selected from the group consisting of matrix metalloprotease-8 ("MMP-8"), matrix metalloprotease-1, matrix metalloprotease-2, matrix metalloprotease-9, matrix metalloprotease-13 and combinations thereof and the truncated receptor for transforming growth factor- β ("TGF- β ") type II.

Claim 23 (Canceled).

24. (Currently amended): A method of treating fibrotic disorders in a patient, comprising:

~~preparing a recombinant adenoviral vector containing a therapeutic gene or DNA sequence of claim 22;~~

~~delivering the composition of claim 22 recombinant adenoviral vector by an intravenous administrative route to an organ a liver; and~~

~~generating expressing the therapeutic protein proteins in the liver organ from the recombinant adenoviral vector of the composition to treat the hepatic fibrotic disorders.~~

Claims 25-27. (Canceled).

28. (Previously presented): The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is MMP-8.

29. (Previously presented): The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is MMP-1.

30. (Previously presented): The pharmaceutical composition according to claim 29, wherein the therapeutic protein for the treatment of fibrotic disorders is the truncated receptor for TGF- β type II.

Claim 31 (canceled)

32. (Previously presented): The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is matrix metalloprotease-2.

33. (Previously presented): The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is matrix metalloprotease-9.

34. (Previously presented): The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is matrix metalloprotease-13.